Natick-based medical device company Boston Scientific Corp. is launching its Promus Element stent system in China.
The company had said it already received registration approval from the Chinese State Food and Drug Administration and will expand sales of the drug-eluting stent system as it receives provincial reimbursement approvals. The stents deliver medication to treat coronary artery disease.
In July, the company’s board of directors approved a five-year, $150-million manufacturing facility project focused on the Chinese market. BSX said then that it expected its revenues from China to reach more than $500 million by the end of 2016.
